Pharmaceutical

PF-07872412 by Pfizer for Streptococcal Pneumonia: Likelihood of Approval

PF-07872412 is under clinical development by Pfizer and currently in Phase I for Streptococcal Pneumonia.

Feb 20, 2024 - 18:00
PF-07872412 is under clinical development by Pfizer and currently in Phase I for Streptococcal Pneumonia.
Read the original article

Tags:

Previous Article

INV-347 by Inversago Pharma for Obesity: Likelihood of Approval

Next Article

NA-921 by Biomed Industries for Rett Syndrome: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eisai joins the ADC golden rush

Eisai joins the ADC golden rush

May 12, 2023

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda co...

May 29, 2024

STAT+: Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million

STAT+: Cour Pharmaceuticals, a biotech taking aim at au...

Jan 30, 2024